Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) is set to make a secondary listing on the Hong Kong Stock Exchange, following approval from its board of directors. Concurrently, the company has entered into a significant agreement with Chongqing Hi-tech Industrial Development Zone and Chongqing CAPC PHARM Big Health Private Equity Investment Fund. This partnership involves an investment of RMB 1.6 billion (USD 219.86 million) into a larger RMB 2 billion (USD 274.83 million) bone health novel drug project.
Investment Boosts Chongqing Hi-tech Industrial Development Zone
The project, which will capitalize on the biological CDMO manufacturing facilities located in the Western (Chongqing) Science City, is anticipated to bring a range of benefits to the Chongqing Hi-tech Industrial Development Zone. These include drug development, drug licenses, commercial manufacturing, commercialization rights, and sales.
Mabwell Bio’s Robust Product Pipeline
Mabwell Bioscience boasts an impressive product pipeline that includes 15 drugs, with 11 being novel drugs and 4 biosimilars. The company has already successfully listed 3 drugs and has 1 drug under marketing review. Additionally, 3 products are currently undergoing pivotal clinical studies, demonstrating Mabwell Bio’s commitment to innovation and development in the pharmaceutical industry.-Fineline Info & Tech
